.jpg)
.png)
Image:
Body:
The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy made in the NLA Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 in 2015.
Category:
Front Page
Dates:
Friday, May 19, 2017 to Friday, August 11, 2017
Link the Feature to::
This page was last updated: Jun 25, 2019